Table C140. Assessment of individual study quality for KQ5 and KQ6

| **Study ID** | **Allocation Concealment** | **Blinding** | **Intention to Treat Analysis** | **WithdrawalsDescribed** | **Study Rating** |
| --- | --- | --- | --- | --- | --- |
| *Angiotensin converting enzyme inhibitor (ACEI) versus placebo/no treatment trials (n=17)* | | | | | |
| Perkovic, 20071  PROGRESS | adequate | double\* | yes | yes for  overall study population\*\* | Good |
| Asselbergs, 20042 | unclear | double\* | yes | yes | Fair |
| Marre, 20043 DIABHYCAR | adequate | double\* | yes | yes | Good |
| Katayama, 20024  JAPAN-IDDM | adequate | double\* | no | yes | Fair |
| Bojestig, 20015 | unclear | double | yes | yes | Fair |
| Gerstein HOPE Trial, 20016 | adequate\*\* | double\* | yes | yes for  overall study population\*\* | Good |
| O’Hare, 20007 ATLANTIS | adequate | double | no | yes | Fair |
| Muirhead, 19998 | unclear | double | no | yes | Fair |
| Ruggenenti, 19999 REIN | adequate | double\* | yes | yes | Good |
| Crepaldi, 199810 | unclear | double | no | yes | Fair |
| The GISEN Group, 199711 | adequate | double\* | yes | yes | Good |
| Maschio, 199612 | unclear | double\* | yes | yes | Fair |
| Trevisan, 199513 | unclear | double | no | yes | Fair |
| Laffel, 199514 | unclear | double | no | yes | Fair |
| Sano 199415 | unclear | no | no | yes | Fair |
| Lewis, 199316 | unclear | double\* | yes | yes | Fair |
| Ravid, 199317 | unclear | double | no | yes | Fair |
| *Angiotensin converting enzyme inhibitor (ACEI) versus angiotensin II-receptor blocker (ARB) trials (n=6)* | | | | | |
| Mann, 200818  ONTARGET | adequate | double | yes | yes | Good |
| Menne, 200819  VALERIA | adequate | double\* | no | yes | Fair |
| Sengul, 200620 | unclear | no | no | yes | Fair |
| Barnett, 200421 DETAIL | adequate | double | yes | yes | Good |
| Lacourcière, 200022 | unclear | double | no | yes | Fair |
| Muirhead, 19998 | unclear | double | no | yes | Fair |
| *Angiotensin converting enzyme inhibitor (ACEI) versus Calcium channel blocker (CCB) trials (n=6)* | | | | | |
| Rahman, 200523,110  ALLHAT | adequate\*\* | double\* | yes | yes for  overall study population\*\* | Good |
| Fogari, 200224 | adequate | no | no | yes | Fair |
| Agodoa, 200225  Wright, 200226  Norris, 200627  (AASK) | adequate\*\* | double\* | yes | yes | Good |
| Marin, 200128 ESPIRAL | unclear | no | yes | yes | Fair |
| Crepaldi, 199810 | unclear | double | no | yes | Fair |
| Zucchelli, 1995/199229,30 | unclear | no | yes | yes | Fair |

| Table C140. Assessment of individual study quality for KQ5 and KQ6 (continued) | | | | | |
| --- | --- | --- | --- | --- | --- |
| **Study ID** | **Allocation Concealment** | **Blinding** | **Intention to Treat Analysis** | **WithdrawalsDescribed** | **Study Rating** |
| *Angiotensin converting enzyme inhibitor (ACEI) versus beta-blocker trials (n=3)* | | | | | |
| Wright, 200226  Norris, 200627  (AASK) | adequate\*\* | double\* | yes | yes | Good |
| van Essen, 199731 | unclear | double | no | yes | Fair |
| Hannedouche, 199432 | adequate | no | yes | yes | Fair |
| *Angiotensin converting enzyme inhibitor (ACEI) versus diuretics trials (n=2)* | | | | | |
| Rahman, 200523,110  ALLHAT | adequate\*\* | double\* | yes | yes for  overall study population\*\* | Good |
| Marre, 200433NESTOR | unclear | double | no (one subject excluded) | yes | Fair |
| *ARB versus placebo trials (n=5)* | | | | | |
| Tobe, 201135  TRANSCEND | adequate\*\* | double\* | yes | yes (for CKD patients) | Good |
| Makino, 200737 | unclear | double | no | yes | Fair |
| Brenner, 200138  RENAAL | adequate | double\* | yes | yes | Good |
| Parving, 200139  IRMA-2 | unclear | double | yes | yes | Fair |
| Lewis, 200140 IDNT | adequate | double\* | yes | yes | Good |
| *ARB versus CCB trials (n=4)* | | | | | |
| Saruta, 200941  CASE-J | unclear | no | yes | no | Fair |
| Ogawa, 200742 | unclear | single (patient) | unclear | yes | Fair |
| Viberti, 200243  MARVAL | adequate | double | yes | yes | Good |
| Lewis, 200140  IDNT | adequate | double\* | yes | yes | Good |
| *ACEI plus ARB versus ACEI or ARB trials (n=1)* | | | | | |
| Tobe, 201135  ON-TARGET | adequate\*\* | double\* | yes | yes (for CKD patients) | Good |
| *ACEI plus ARB versus ACEI trials (n=5)* | | | | | |
| Sengul, 200620 | unclear | no | no | yes | Fair |
| Menne, 200819 VALERIA | adequate | double\* | no | yes | Fair |
| Kanno, 200644 | unclear | no | no | yes | Fair |
| Mehdi, 200945 | unclear | double | no (one subject excluded) | yes | Fair |
| Anand, 200946 | adequate | double | yes | yes | Good |
| *ACEI plus ARB versus ARB trials (n=2)* | | | | | |
| Sengul, 200620 | unclear | no | no | yes | Fair |
| Menne, 200819 VALERIA | adequate | double\* | no | yes | Fair |
| *ACEI plus ARB versus ACEI plus aldosterone antagonist trial* | | | | | |
| Mehdi, 200945 | unclear | double | no (one subject excluded) | yes | Fair |
| *ACEI plus CCB versus ACEI monotherapy or CCB monotherapy trial* | | | | | |
| Fogari 2002 | adequate | no | no | yes | Fair |
| *ACEI plus diuretic versus ACEI plus CCB trials (n=2)* | | | | | |
| Bakris, 201048  (ACCOMPLISH) | adequate\*\* | double\* | yes for overall study population | yes for overall study population | Good |
| Bakris, 200847 (GUARD) | adequate | double | no | yes | Fair |
| *ACEI plus diuretic versus ACEI trial* | | | | | |
| Mogensen, 200350 | unclear | double | no | no | Fair |
| *ACEI plus diuretic versus placebo trial* | | | | | |
| Lambers Heerspink 201051  ADVANCE | adequate\*\* | double\* | yes for overall study population | yes for overall study population | Good |
| *ARB versus different ARB trials (n=2)* | | | | | |
| Bakris, 200853 (AMADEO) | unclear | double | no | no | Fair |
| Galle, 200854 | unclear | double | yes | yes | Fair |
| *ARB (high dose) versus ARB (standard dose) trials* | | | | | |
| Burgess, 200955 | adequate | double | yes | yes | Good |
| Makino, 200737 | unclear | double | no | yes | Fair |
| Parving, 200139  IRMA-2 | unclear | double | yes | yes | Fair |
| *ACEI plus aldosterone antagonist versus ACEI trial* | | | | | |
| Mehdi, 200945 | unclear | double | no (one subject excluded) | yes | Fair |
| *ACEI/ARB plus aldosterone antagonist versus ACEI/ARB trial* | | | | | |
| van den Meiracker, 200656 | adequate | double | no | yes | Fair |
| *Beta blocker versus placebo trials (n=2)* | | | | | |
| Cohen-Solal, 200957  Flather, 200558  SENIORS | adequate\*\* | double\* | no | unclear | Fair |
| Ghal, 200959  MERIT-HF | adequate | double | yes | yes | Good |
| *CCB versus placebo trials (n=2)* | | | | | |
| Berl, 200360  Lewis, 200140 | adequate | double | yes | yes | Good |
| Crepaldi, 199810 | unclear | double | no | yes | Fair |
| *Diuretic versus placebo trial* | | | | | |
| Pahor, 199861 | adequate | double | yes | yes | Good |
| *ACEI versus conventional therapy without ACEI trial* | | | | | |
| Cinotti, 200162 | unclear | no | yes | no | Fair |
| *CCB versus BB trials (n=3)* | | | | | |
| Bakris, 199663 | unclear | unclear | yes | yes | Fair |
| Wright, 200226  AASK | adequate\*\* | double\* | no | yes | Good |
| Dahlof, 200565 | adequate | open-label\* | yes | yes | Good |
| *CCB versus diuretic trial* | | | | | |
| Rahman 2006  ALLHAT | adequate\*\* | double\* | yes | yes for  overall study population\*\* | Good |
| *Strict versus standard blood pressure control trials (n=6)* | | | | | |
| Ruggenenti, 200566  REIN-2 | adequate | no | no, 3 subjects excluded | yes | Fair |
| Wright, 200226  AASK | adequate\*\* | no | yes | yes | Good |
| Estacio 2000 - Study B  ABCD | unclear | “blinded,” unclear if double-blinded\* | unclear | yes | Fair |
| Lewis, 199969 | unclear | unclear | yes | no | Fair |
| Toto, 199570 | unclear | double | yes | unclear | Fair |
| Peterson, 199571  Klahr, 199472  MDRD, Study A | unclear | unclear | yes | yes | Fair |
| Shulman, 198974  HDFP | adequate | no | no | no | Fair |
| *Anti-lipid trials: HMG-CoA reductase inhibitor versus placebo trials (n=12)* | | | | | |
| Kendrick, 201087  AFCAPS/ TexCAPS | unclear | double\* | yes | yes for  overall study population\*\* | Fair |
| Ridker, 2010  JUPITER | adequate\*\* | double\* | yes | yes for  overall study population\*\* | Good |
| Nakamura, 200989 MEGA | adequate\*\* | open-label | no (382 excluded from analyses)\*\* | yes for  overall study population\*\* | Fair |
| Colhoun, 200990  CARDS | adequate\*\* | double\* | no (3 randomized patients were excluded - investigators  realized they did not meet the entry criteria before they  actually took their first dose of study drug) | yes for  overall study population\*\*n | Good |
| Koren, 200991  ALLIANCE | adequate | open-label | yes | yes for  overall study population\*\* | Good |
| Rahman, 200893  ALLHAT-LLT | adequate\*\* | open-label\* | no for CKD subgroups (need valid baseline eGFR); yes for overall study population | yes (for CKD patients) | Good |
| Chonchol, 200794 4S | adequate\*\* | double\* | no (24 excluded, no serum creatinine at baseline) | partially for  overall study population\*\* | Fair |
| Kjekshus, 200796  CORONA | adequate\*\* | double\* | yes | yes | Good |
| Lemos, 200597  LIPS | unclear | double\* | yes | yes for  overall study population\*\* | Fair |
| Asselbergs, 20042 PREVD | unclear | double\* | yes | yes | Fair |
| Tonelli, 200498  WOSCOPS/ CARE/LIPID | adequate\*\* | double\* | yes | yes for  overall study populations for CARE, LIPID; no for WOSCOPS\*\* | Good |
| Tonelli, 200399  CARE | adequate | double\* | yes | yes for  overall study population\*\* | Good |
| *Anti-lipid trials:**high versus low dose HMG-CoA reductase inhibitor trial* | | | | | |
| SEARCH, 2010100 | adequate | double\* | yes | yes | Good |
| Shepherd, 2008101 TNT | unclear | double\* | no | yes (for CKD patients) | Fair |
| *Anti-lipid trials: HMG-CoA reductase inhibitor versus bile acid sequestrant trial* | | | | | |
| Tonolo, 2006104 | unclear | double | yes | yes | Fair |
| *Anti-lipid trials: Gemfibrozil versus placebo/control trials (n=2)* | | | | | |
| Tonelli, 200498  VA-HIT | adequate | double\* | yes | yes for  overall study population\*\* | Good |
| Samuelsson, 199784 | unclear | open-label | no | yes | Fair |
| *Low protein diet versus usual protein diet and other dietary intervention trials (n=9)* | | | | | |
| Koya, 200975 | adequate | no | no | yes | Fair |
| Dussol, 200576 | unclear | no | no | yes | Fair |
| Kopple, 199777  Peterson, 199571  Klahr, 199472  Greene, 199373  MDRD | adequate | double for followup GFRs | unclear | yes | Fair |
| D’Amico, 199478 | unclear | no | no | no | Fair |
| Locatelli, 199179 | adequate | unclear | no | yes | Fair |
| Rosman, 1989/198480,81 | unclear | no | no | no | Fair |
| Facchini, 200382 | unclear | study personnel blinded to aim of study | no | yes | Fair |
| Williams, 199183 | adequate | no | no | no | Fair |
| Samuelsson, 199784 | unclear | no | no | yes | Fair |
| *Glycemic control trials (n=2)* | | | | | |
| Duckworth, 200985 | adequate | open-label\* | yes | yes | Good |
| Microalbuminuria Collaborative, 199586 | adequate | open-label | yes | yes | Good |
| *Intensive multi-component intervention trials (n=4)* | | | | | |
| Chan, 2009105 | adequate | open-label | yes | yes | Good |
| Joss, 2004106 | adequate | open-label | no | yes | Fair |
| Gaede, 2003/1999107,108 | adequate | open-label | no | yes | Fair |
| Harris, 1998109 | unclear | open-label | yes | yes | Fair |

\*In addition, end points/clinical outcomes were adjudicated by blinded committee  
\*\* Detailed in baseline/study design or main findings manuscript. Included study was a secondary/post-hoc analysis with subgroup(s) of CKD patients.